Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2019

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

Master the marketplace

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Relevant products

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Scrip: industry news and insights

Key benefits:

Follow market developments
Go beyond the news
Hear from news makers

Biomedtracker: follow the drug development process

Track and assess key events that will impact a drug’s probability of technical success and approval.

Key benefits:

Stay up to date
Get ahead of the competition
Conference coverage

View all content

Scrip

In NASH, Gilead Swung For The Fences And Struck Out Again

By Joseph Haas 14 Feb 2019

Gilead took a risky approach with selonsertib in NASH, pursuing a tough liver fibrosis benefit and failing, continuing a trend of disappointments outside of its antiviral franchises. Analysts don’t expect the second Phase III study in less-sick patients to succeed either.

Topic Drug review Drug approval Drug development landscape Clinical trials

View article
Scrip

Keytruda/Inlyta Data Stoke Competition In Kidney Cancer

By John Davis 14 Feb 2019

Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.

Topic Cancer

View article
Scrip

Novartis Pharma CEO Sees Zolgensma Supplanting Spinraza

07 Feb 2019

The Swiss major's pharma chief tells Scrip that its gene therapy for SMA offers much more than Biogen's Spinraza for both patients and payers, noting that the company is ready with alternative payment models for the pricey treatment as soon as approvals for Zolgensma are granted.

Topic Business strategies Drug approval Drug development landscape Drug review

View article
Scrip

Roche Makes Case For Its Oral SMA Drug Risdiplam As Filings Beckon

By Alexandra Shimmings 07 Feb 2019

Novartis may be turning up the rhetoric in spinal muscular atrophy as its cutting-edge gene therapy Zolgensma approaches a market currently enjoyed solely by Biogen’s Spinraza, but Roche is upbeat about the potential of its investigational oral product, risdiplam, to weigh in.

Topic Business strategies Drug approval Drug development landscape

View article
Scrip

Q4 Pharma Earnings Preview: Roche, Celgene, Novo Nordisk, Merck, Gilead

By Alexandra Shimmings 01 Feb 2019

Roche will highlight newer drugs as cancer blockbusters feel biosimilar pressure, while Celgene will talk to investors about its pending acquisition by Bristol. Novo Nordisk has faced concerns about generic and branded competition not to mention price pressures, but its longer-term outlook is sound; Merck's Keytruda tops investors' focus; Gilead looks ahead to new CEO O'Day.

Topic Biosimilars Business strategies Drug approval Drug development landscape Drug review

View article
Scrip

Infographic: The Netherlands, A Small Country With Big Ideas

By Jo Shorthouse 01 Feb 2019

As the EMA lowers the flags of the 28 EU nations that have flown outside its London offices for 24 years, and prepares to moves its HQ to the Netherlands, Scrip takes a look at Europe’s new pharma regulatory hub.

Topic Business strategies Brexit

View article
Scrip

Rare But Real: How One Startup Is Willing Itself To Lift China Orphan Drug Market

By Brian Yang 23 Jan 2019

As a promising market for orphan drugs, China has seen several approvals in this space in the past six months, mostly from multinationals. But Beijing-based CANbridge believes that a smaller biotech also has a good shot at a leadership role, despite a lack of funding and reimbursement and prickly pricing issues.

Topic Drug approval Drug development landscape Drug review

View article
Scrip

J&J Expects Persistent Pricing Pressure Into 2019

By Jessica Merrill 23 Jan 2019

CEO Alex Gorsky highlighted growing public concern over US drug costs during J&J's Q4 earnings call, pressing for more transparency and value-based health care. The company's net drug prices declined more than 6% in 2018, he added.

Topic Drug review Business strategies

View article
Scrip

Monumental Year Ahead For Korean Pharmas As New US Approvals Eyed

By Jung Won Shin 16 Jan 2019

2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.

Topic FDA Business strategies

View article
Scrip

The Gene Therapies Are Coming – And So Are New Ways To Pay For Them

By Jessica Merrill 16 Jan 2019

Annual payment plans for gene therapies appear closer to becoming reality now that bluebird bio detailed plans at J.P. Morgan. Novartis, Sarepta and others are also talking to payers about alternative payment models. Harvard Pilgrim's Michael Sherman applauded the effort in an interview.

View article
Datamonitor Healthcare

Clinical Breakthroughs in Urological Cancers can be a Double-Edged Sword as Payers are Forced to Act

By Louisa Joseph 10 Jan 2019

The three urological cancers are undergoing tremendous changes in treatment practices as a result of new product launches and indication expansions.

Topic Cancer

View white paper
Scrip

Scrip Asks... What Will 2019 Hold For Biopharma? Part 1: Therapeutic Advances

By Eleanor Malone 10 Jan 2019

Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.

Topic Research Business strategies BioPharmaceutical

View article
Scrip

J.P. Morgan Notebook Day 1: Pfizer, Gilead, Alnylam, Novartis, Sarepta, Deal Trends And Cell Therapy Challenges

By Jessica Merrill 10 Jan 2019

News and notes from the 2019 J.P. Morgan Healthcare Conference. Pfizer CEO Bourla underscores need for scientific and commercial innovation, Gilead makes M&A a priority, Novartis' new R&D chief reflects on first meeting with CEO Narasimhan, Sarepta CEO Ingram clarifies regulatory path for micro-dystrophin, J.P. Morgan outlines deal and macro biopharma trends in 2019, and cell therapy panel discusses manufacturing challenges.

Topic BioPharmaceutical Cell and gene therapy

View article
Datamonitor Healthcare

Neuropathic Pain Market and Forecast Analysis to 2026

By Nicola Sawalhi-Leckenby 07 Jan 2019

Big changes are coming to the neuropathic pain market – are you prepared? Take a look at the projected neuropathic pain drug sales for the US, Japan, and five EU nations with the latest infographic from Datamonitor Healthcare. This snapshot view of the future of the neuropathic pain market is packed with data from the full Datamonitor Healthcare Neuropathic Pain Disease Coverage report.

View infographic
Scrip

Industry and Investors Underestimate Clinical Trials Performances

By Mike Ward 07 Jan 2019

Researchers from the MIT Laboratory for Financial Engineering, using clinical trials data provided by Informa Pharma Intelligence, have developed algorithms that provide a more timely, accurate and optimistic estimate of the risks and rewards of clinical trials.

Topic Business strategies Clinical trials

View article

Latest headlines

Scrip

15 Feb 2019

Pressure Builds On Lundbeck After Rexulti Fails In Bipolar I Manic Episodes

Link
Scrip

15 Feb 2019

AZ And Ipsen Outline Brexit Contingency Plans

Link
Scrip

15 Feb 2019

Deal Watch: Roivant Spins Out Arvelle, Licenses Epilepsy Candidate From SK Biopharma

Link
Scrip

15 Feb 2019

AZ China Growth Pops Again But Clouds Loom

Link
Scrip

15 Feb 2019

Bruised Roche Wins Another UK Perjeta Round With Price Cut

Link
Scrip

14 Feb 2019

Interview: Janssen Builds Japan Specialty Interests But Wants Ongoing Policy Debate

Link
Scrip

14 Feb 2019

Tagrisso Climbs Close To Top Of AstraZeneca Sales Tree

Link
Scrip

14 Feb 2019

Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer

Link
Scrip

14 Feb 2019

Glenmark Spins Out Innovation With New US Base

Link
Scrip

14 Feb 2019

Venture Funding Deals: Vedanta Raises More Cash To Advance Microbiome Candidates

Link
Scrip

14 Feb 2019

Farewell To MedImmune: AstraZeneca Will Combine Large And Small Molecule Research

Link
Scrip

14 Feb 2019

Janssen’s Esketamine Gets US FDA Panel Endorsement, But With Pricing, Access And Diversion Concerns

Link
Scrip

14 Feb 2019

Analysts Upbeat On Aurobindo After Strong Earnings

Link
Scrip

14 Feb 2019

Orphan Drug Makers Get Selected Tax Breaks As China Turns To Access

Link
Scrip

14 Feb 2019

Korean Firms Join Hands To Pick Up Troubled US Cancer Vaccine Firm Argos

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Get ahead with in-depth pharmaceutical competitive intelligence

​Master the marketplace

Relevant products

Below are the Product List

Datamonitor Healthcare: data analysis and insight

Scrip: industry news and insights

Biomedtracker: follow the drug development process

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Pharma Report Store

Master the marketplace